BCAX
Bicara Therapeutics Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$23.17
−0.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 132.1M | 125.1M | 63.6M | 30.6M | 31.3M |
| SG&A Expense | 42.8M | 30.5M | 18.8M | 9.3M | 6.3M |
| General & Admin Expense | 42.8M | 30.5M | 18.8M | 9.3M | 6.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 27.2M | — | — | — | — |
| Total Operating Expenses | 202.0M | 155.6M | 82.4M | 39.9M | 37.7M |
| Cost and Expenses | 202.0M | 155.6M | 82.4M | 39.9M | 37.7M |
| Operating Income (EBIT) | (202.0M) | (155.6M) | (82.4M) | (39.9M) | (37.7M) |
| Non-Operating | |||||
| Interest Income | 16.8M | 17.9M | 14.6M | 1.3M | 4.0K |
| Interest Expense | — | — | — | — | 112.0K |
| Net Interest Income | 16.8M | 17.9M | 14.6M | 1.3M | (108.0K) |
| Other Non-Op Income/Expense | 16.8M | 17.9M | 14.6M | (12.1M) | (188.0K) |
| Non-Operating Income (excl Interest) | (16.8M) | (17.9M) | (14.6M) | 12.1M | 76.0K |
| EBT (Pre-Tax Income) | (185.2M) | (137.7M) | (67.8M) | (52.0M) | (37.8M) |
| Income Tax Expense | 102.0K | 217.0K | 187.0K | 5.0K | 1.0K |
| Bottom Line | |||||
| Net Income | (185.4M) | (137.9M) | (68.0M) | (52.0M) | (37.8M) |
| Earnings from Cont. Ops | (185.3M) | (137.9M) | (68.0M) | (52.0M) | (37.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (185.4M) | (137.9M) | (68.0M) | (52.0M) | (37.8M) |
| Per Share | |||||
| Basic EPS | ($3.10) | ($2.52) | ($1.25) | ($1.00) | ($0.73) |
| Diluted EPS | ($3.10) | ($2.52) | ($1.25) | ($1.00) | ($0.73) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 67.9M | 54.7M | 54.4M | 51.8M | 51.8M |
| Diluted Shares Outstanding | 67.9M | 54.7M | 54.4M | 51.8M | 51.8M |
| Profitability Metrics | |||||
| EBITDA | (184.4M) | (137.6M) | (67.8M) | (52.0M) | (37.7M) |
| D&A | 774.0K | 105.0K | 56.0K | 19.0K | 10.0K |
| EBIT | (185.2M) | (137.7M) | (67.8M) | (52.0M) | (37.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026